GABA_A五种亚型受体与BZ配基的3D-QSAR研究

GABAA受体是中枢神经系统内重要的抑制性受体,有广泛的神经生理活性.由于镇静/抗惊厥药物在临床上的广泛应用,使得其中苯并二氮杂作用位点尤为重要.我们用比较分子场法(CoMFA)对一系列咪唑苯并二氮杂类化合物(BZ)与五种重组受体亚型的亲和力进行了结构活性关系研究,得到的一组模型都有较高的交叉验证系数.并在此基础上,建立了非交叉验证的一组PLS模型.用该组模型对随机选择的6个化合物组成的测试集进行了预测,都得到了相当满意的结果,表明所建立的一组模型具有良好的预测能力.本研究对于设计高亲和力的BZ受体的配基和研究GABAA受体的模型有指导意义.     

家蝇与大鼠GABA受体抑制剂的药效团模型及其3D-QSAR研究

采用DISCOtech方法,用7个大鼠γ-氨基丁酸(GABA)A受体抑制剂和11个家蝇GABAA受体抑制剂分别建立了其药效团模型;用CoMFA方法建立了22个大鼠GABAA受体抑制剂和29个家蝇GABAA受体抑制剂的3D-QSAR模型,模型的交叉验证相关系数分别为0.526和0.679,验证了药效团模型的合理性,为设计更高活性和更高选择性的化合物提供了参考     

GABAA受体萜类抑制剂构效关系研究

采用DISCOtech方法建立了大鼠和家蝇GABAA受体萜类抑制剂的药效团模型, 根据药效团模型叠加规则建立了大鼠和家蝇GABAA受体萜类抑制剂CoMFA模型, 模型的交叉验证相关系数分别为0.713和0.738. 构效关系研究显示， 家蝇和大鼠受体抑制剂结合部位之间存在一个主要差别: 与受体作用的抑制剂的负电荷基团取代有利于保持其对哺乳动物的高抑制活性, 而保持对昆虫的高抑制活性是不需要的, 从而为寻找先导化合物和设计高选择性杀虫剂提供了理论指导.     

磺胺基羟肟酸类HDAC抑制剂三维定量构效关系

组蛋白去乙酰化酶(HDAC)对染色质分布和基因调节起着重要的作用,也是治疗癌症和其它疾病的新靶点.羟肟酸类抑制剂是目前研究最多的组蛋白去乙酰化酶抑制剂.应用比较分子力场(CoMFA)法对一系列磺胺基羟肟酸类HDAC抑制剂进行了结构活性关系研究,得到的模型具有较高的交叉验证系数(q²=0.704).并在此基础上,建立了非交叉验证的偏最小二乘分析(PLS)模型.用该模型对随机选择的6个化合物组成的测试集进行了预测,得到了令人满意的结果,所建模型具有良好的预测能力.本研究对于设计高活性的HDAC抑制剂及抗癌药物都有指导意义.     

5,6-二氢-(9H)-吡唑[3,4-c]-1,2,4-三唑[4,3-a]吡啶类抑制剂的HQSAR研究

应用分子全息定量构效关系(HQSAR)分析方法,以5,6-二氢-(9H)-吡唑[3,4-c]-1,2,4-三唑[4,3-a]吡啶类抑制剂为研究对象,建立了一组对磷酸二酯酶4有抑制活性的化合物HQSAR模型,分析化合物活性与分子结构之间的关系.探讨了分子全息长度、分子碎片大小以及碎片区分参数对模型质量的影响.最优模型的交叉验证相关系数q2=0.628,非交叉验证相关系数r2=0.930,标准偏差SE=0.277.该模型具有较好的预测能力,对该类化合物性质的预测及进一步合成工作有指导意义.     

新型5-HT重摄取抑制剂的设计、合成及活性评价

在对已知各种结构类型的5-HT重摄取抑制剂分子结构全面分析的基础上, 建立了SSRIs药效团模型. 基于该模型应用UNITY程序对NCI-3D和Maybridge-3D数据库进行三维结构的限制性查询, 在获得的命中结构的信息指导下, 设计合成了3种全新结构类型的化合物, 并完成了初步的药理活性评价. 这些化合物均显示出不同程度的5-HT重摄取抑制活性, 其中5个化合物显示高抑制活性. 哌嗪取代的二苯脒类化合物的结构新颖, 较好地符合5-HT重摄取抑制剂药效团模型, 与SSRIs类化合物三维定量构效关系研究得到的CoMFA模型有较好的适配性.     

化合物色谱保留参数与其三维结构关系的研究

利用比较分子场分析(CoMFA)方法,建立了烷基取代苯、氯代苯、多环芳烃和二硝基取代芳烃等4类结构相近的化合物在甲醇／水体系中反相C18柱上的保留参数a,c值与其三维结构之间关系的定量模型。前3类化合物所得到的3个模型的交叉验证相关系数q2均大于0.5,其中针对烷基取代苯、氯代苯所建立的两个模型的非交叉验证相关系数r2大于0.995,表明模型具有较好的预测能力。该研究结果对进一步开展化合物液相色谱保留参数与其三维结构关系的研究提供了思路和方法。     

电拓扑状态预测多氯二苯并噻吩及噻吩砜化合物的气相色谱保留指数

以原子类型电拓扑状态指数(ETSI)有效表征了135 个多氯二苯并噻吩(PCDT)和135 个多氯二苯并噻吩砜(PCDTO₂)的分子结构, 应用基于预测的变量选择与模型化(VSMP)方法建立PCDT 和PCDTO₂ 化合物在DB-5 气相色谱柱上的气相色谱保留指数(RI)与分子结构(ETSI)的定量相关模型, 模型的相关系数r² 分别为0.9939 和0.9729, LOO 交叉验证相关系数 q² 分别为0.9921 和0.9692. 为验证模型稳定性和预测能力, 应用17 个PCDT 和PCDTO₂ 训练集样本构建的QSRR 模型的r² 分别为0.9959 和0.9783, LOO 交叉验证相关系数 q² 分别为0.9921 和0.9740, 说明模型具有良好的稳定性. 以此模型预测外部8 个检验集及110 个预测集的RI 值, 8 个检验集样本的结果表明训练集模型具有良好预测能力.     

q~2引导构象选择CoMFA方法研究HIV－1RT抑制剂

对未知受体结构的药物设计其主导方法CoMFA来说，柔性目标分子的多种构象 造成了问题的复杂性。本文介绍交叉验证参数R~2(q~2)引导的构象选择CoMFA方法 ，选择化合物的最佳构象。将一组47个HIV－1 RT抑制剂进行有、无构象选择的 CoMFA分析来作评价。根据化合物的活性、毒性、选择性指数（毒性／活性比）等 实验数据得到的模型，其交叉验证参数q~2为0.7以上，非交叉验证的相应参数为0. 94以上，最后，还经过试验集化合物验证该模型的预测能力，置信度（1－α）＞ 0.99。     

1,5-苯并二氮杂(艹卓)衍生物的合成及其生物活性的研究进展

1,5-苯并二氮杂(艹/卓)是一类具有广泛的生理活性和药理活性的七元杂环化合物,很多化合物已作为临床药物,具有很高的研究价值和应用前景,而其合成方法的研究已成为有机化学的一个热点,综述了1,5-苯并二氮杂(艹/卓)的生理活性、医药方面的应用,以及双环化合物合成方法的最新研究进展.     

Pseudoreceptor models and 3D-QSAR for imidazobenzodiazepines at GABA A/BzR subtypes alphaxbeta3gamma2 [x = 1-3, 5, and 6] via flexible atom receptor model

Since benzodiazepines have been used widely in the treatment of anxiety, sleeplessness, and epilepsy, the receptor sites for the benzodiazepine are of prime importance. Quantitative structure-activity relationship (QSAR) studies and receptor modeling via Flexible Atom Receptor Model (FLARM) for the binding affinities of a series of imidazobenzodiazepines at five recombinant receptor subtypes were carried out successfully. The 3D-QSAR models for all five receptor subtypes were examined by a set of test set and demonstrated their high predictability for affinities of imidazobenzodiazepines at five receptor subtypes. The pseudoreceptors yielded by FLARM were compared to the united pharmacophore/receptor model. The result shows that two hydrogen bonds and other regions in the united pharmacophore/receptor model are presented in the pseudoreceptors, which demonstrates the receptor modeling capability of FLARM. The models and pseudoreceptors can help design high affinity ligands on the GABA(A)/BZ receptor and understand the GABA(A) receptor.     

A pharmacophore model for dopamine D4 receptor antagonists

A pharmacophore model for dopamine D₄ antagonists has been developed on the basis of a previously reported dopamine D₂ model. By using exhaustive conformational analyses (MM3^* force field and the GB/SA hydration model) and least-squares molecular superimposition studies, a set of eighteen structurally diverse high affinity D₄ antagonists have successfully been accommodated in the D₄ pharmacophore model. Enantioselectivities may be rationalized by conformational energies required for the enantiomers to adopt their proposed bioactive conformations. The pharmacophore models for antagonists at the D₄ and D₂ receptor subtypes have been compared in order to get insight into molecular properties of importance for D₂/D₄ receptor selectivity. It is concluded that the bioactive conformations of antagonists at the two receptor subtypes are essentially identical. Receptor essential volumes previously identified for the D₂ receptor are shown to be present also in the D₄ receptor. In addition, a novel receptor essential volume in the D₄ receptor, not present in the D₂ receptor, has been identified. This feature may be exploited for the design of D₄ selective antagonists. However, it is concluded that the major determinant for D₂/D₄ selectivity is the nature of the interactions between the receptor and aromatic ring systems. The effects of the electronic properties of these ring systems on the affinities for the two receptor subtypes differ substantially.     

Synthesis,Docking Studies and Pharmacological Evaluation of Serotoninergic Ligands Containing a 5-Norbornene-2-Carboxamide Nucleus

A new series of 5-norbornene-2-carboxamide derivatives was prepared and their affinities to the 5-HT_1A, 5-HT_2A, and 5-HT_2C receptors were evaluated and compared to a previously synthesized series of derivatives characterized by exo-N-hydroxy-5-norbornene-2,3-dicarboximidenucleus, in order to identify selective ligands for the above-mentioned subtype receptors. Arylpiperazines represents one of the most important classes of 5-HT_1AR ligands, and recent research concerning new derivatives has been focused on the modification of one or more portions of such pharmacophore. The combination of structural elements (heterocyclic nucleus, propyl chain and 4-substituted piperazine), known to be critical to the affinity to 5-HT_1A receptors, and the proper selection of substituents led to compounds with high specificity and affinity towards serotoninergic receptors. The most active compounds were selected for further in vivo assays to determine their functional activity. Finally, to rationalize the obtained results, molecular docking studies were performed. The results of the pharmacological studies showed that Norbo-4 and Norbo-18 were the most active and promising derivatives for the serotonin receptor considered in this study.     

A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?

The A_2A adenosine receptor (A_2AAR) is one of the four subtypes activated by nucleoside adenosine, and the molecules able to selectively counteract its action are attractive tools for neurodegenerative disorders. In order to find novel A_2AAR ligands, two series of compounds based on purine and triazolotriazine scaffolds were synthesized and tested at ARs. Compound 13 was also tested in an in vitro model of neuroinflammation. Some compounds were found to possess high affinity for A_2AAR, and it was observed that compound 13 exerted anti-inflammatory properties in microglial cells. Molecular modeling studies results were in good agreement with the binding affinity data and underlined that triazolotriazine and purine scaffolds are interchangeable only when 5- and 2-positions of the triazolotriazine moiety (corresponding to the purine 2- and 8-positions) are substituted.     

Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer’s Disease

The A_2A adenosine receptor is a protein belonging to a family of four GPCR adenosine receptors. It is involved in the regulation of several pathophysiological conditions in both the central nervous system and periphery. In the brain, its localization at pre- and postsynaptic level in striatum, cortex, hippocampus and its effects on glutamate release, microglia and astrocyte activation account for a crucial role in neurodegenerative diseases, including Alzheimer’s disease (AD). This ailment is considered the main form of dementia and is expected to exponentially increase in coming years. The pathological tracts of AD include amyloid peptide-β extracellular accumulation and tau hyperphosphorylation, causing neuronal cell death, cognitive deficit, and memory loss. Interestingly, in vitro and in vivo studies have demonstrated that A_2A adenosine receptor antagonists may counteract each of these clinical signs, representing an important new strategy to fight a disease for which unfortunately only symptomatic drugs are available. This review offers a brief overview of the biological effects mediated by A_2A adenosine receptors in AD animal and human studies and reports the state of the art of A_2A adenosine receptor antagonists currently in clinical trials. As an original approach, it focuses on the crucial role of pharmacokinetics and ability to pass the blood–brain barrier in the discovery of new agents for treating CNS disorders. Considering that A_2A receptor antagonist istradefylline is already commercially available for Parkinson’s disease treatment, if the proof of concept of these ligands in AD is confirmed and reinforced, it will be easier to offer a new hope for AD patients.     

Development of Bicyclo[3.1.0]hexane-Based A3 Receptor Ligands: Closing the Gaps in the Structure–Affinity Relationships

The adenosine A₃ receptor is a promising target for treating and diagnosing inflammation and cancer. In this paper, a series of bicyclo[3.1.0]hexane-based nucleosides was synthesized and evaluated for their P1 receptor affinities in radioligand binding studies. The study focused on modifications at 1-, 2-, and 6-positions of the purine ring and variations of the 5′-position at the bicyclo[3.1.0]hexane moiety, closing existing gaps in the structure–affinity relationships. The most potent derivative 30 displayed moderate A₃AR affinity (Ki of 0.38 μM) and high A₃R selectivity. A subset of compounds varied at 5′-position was further evaluated in functional P2Y₁R assays, displaying no off-target activity.     

Environment-Sensitive Fluorescence of 7-Nitrobenz-2-oxa-1,3-diazol-4-yl (NBD)-Labeled Ligands for Serotonin Receptors

Serotonin is a neurotransmitter that plays a crucial role in the regulation of several behavioral and cognitive functions by binding to a number of different serotonin receptors present on the cell surface. We report here the synthesis and characterization of several novel fluorescent analogs of serotonin in which the fluorescent NBD (7-nitrobenz-2-oxa-1,3-diazol-4-yl) group is covalently attached to serotonin. The fluorescent ligands compete with the serotonin_1A receptor specific radiolabeled agonist for binding to the receptor. Interestingly, these fluorescent ligands display a high environmental sensitivity of their fluorescence. Importantly, the human serotonin_1A receptor stably expressed in CHO-K1 cells could be specifically labeled with one of the fluorescent ligands with minimal nonspecific labeling. Interestingly, we show by spectral imaging that the NBD-labeled ligand exhibits a red edge excitation shift (REES) of 29 nm when bound to the receptor, implying that it is localized in a restricted microenvironment. Taken together, our results show that NBD-labeled serotonin analogs offer an attractive fluorescent approach for elucidating the molecular environment of the serotonin binding site in serotonin receptors. In view of the multiple roles played by the serotonergic systems in the central and peripheral nervous systems, these fluorescent ligands would be useful in future studies involving serotonin receptors.     

N-Aryl Isoleucine Derivatives as Angiotensin?II AT2 Receptor Ligands

A novel series of ligands for the recombinant human AT₂ receptor has been synthesized utilizing a fast and efficient palladium-catalyzed procedure for aminocarbonylation as the key reaction. Molybdenum hexacarbonyl [Mo(CO)₆] was employed as the carbon monoxide source, and controlled microwave heating was applied. The prepared N-aryl isoleucine derivatives, encompassing a variety of amide groups attached to the aromatic system, exhibit binding affinities at best with K_i values in the low micromolar range versus the recombinant human AT₂ receptor. Some of the new nonpeptidic isoleucine derivatives may serve as starting points for further structural optimization. The presented data emphasize the importance of using human receptors in drug discovery programs.     

Cancer-Related Somatic Mutations in Transmembrane Helices Alter Adenosine A1 Receptor Pharmacology

Overexpression of the adenosine A₁ receptor (A₁AR) has been detected in various cancer cell lines. However, the role of A₁AR in tumor development is still unclear. Thirteen A₁AR mutations were identified in the Cancer Genome Atlas from cancer patient samples. We have investigated the pharmacology of the mutations located at the 7-transmembrane domain using a yeast system. Concentration–growth curves were obtained with the full agonist CPA and compared to the wild type hA₁AR. H78L^3.23 and S246T^6.47 showed increased constitutive activity, while only the constitutive activity of S246T^6.47 could be reduced to wild type levels by the inverse agonist DPCPX. Decreased constitutive activity was observed on five mutant receptors, among which A52V^2.47 and W188C^5.46 showed a diminished potency for CPA. Lastly, a complete loss of activation was observed in five mutant receptors. A selection of mutations was also investigated in a mammalian system, showing comparable effects on receptor activation as in the yeast system, except for residues pointing toward the membrane. Taken together, this study will enrich the view of the receptor structure and function of A₁AR, enlightening the consequences of these mutations in cancer. Ultimately, this may provide an opportunity for precision medicine for cancer patients with pathological phenotypes involving these mutations.